Evidence map›Paper›PMID 36480093›Full record

ArticleHead and neck pathology2023

A Subset of Salivary Intercalated Duct Lesions Harbors Recurrent CTNNB1 and HRAS Mutations: A Molecular Link to Basal Cell Adenoma and Epithelial-Myoepithelial Carcinoma?

Anne C McLean, Lisa M Rooper, Jeffrey Gagan, Lester D R Thompson, Justin A Bishop

Open access · greenAbstract read
In one paragraph

Article in Head and neck pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Epithelial-myoepithelial carcinoma of the parotid gland: Case report.International journal of surgery case reports · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Anne C McLean *Department of Pathology, University of Texas Southwestern Medical Center, 6201 Harry Hines Blvd Room UH04.250, Dallas, TX, 75390, USA.
Lisa M Rooper *Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Jeffrey GaganDepartment of Pathology, University of Texas Southwestern Medical Center, 6201 Harry Hines Blvd Room UH04.250, Dallas, TX, 75390, USA.
Lester D R ThompsonHead and Neck Pathology Consultations, Woodland Hills, CA, USA.
Justin A BishopDepartment of Pathology, University of Texas Southwestern Medical Center, 6201 Harry Hines Blvd Room UH04.250, Dallas, TX, 75390, USA. Justin.Bishop@UTSouthwestern.edu.ORCID http://orcid.org/0000-0002-9743-4360
The University of Texas Southwestern Medical Center · USJohns Hopkins Hospital · USSouthwestern Medical Center · USWoodland Hills Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntercalated duct lesions (IDLs) are benign salivary gland proliferations that resemble normal intercalated ducts and are subdivided into hyperplastic, adenoma or hybrid types depending on circumscription. While IDLs were historically regarded as non-neoplastic, frequent association with basal cell adenoma (BCA) and epithelial-myoepithelial carcinoma (EMC) has raised the possibility that they are neoplastic precursors.

methodsIn this study, we performed β-catenin immunohistochemistry and targeted molecular analysis on IDLs to clarify their pathogenesis.

resultsWe identified 15 IDLs from the parotid glands of eight men and six women with a median age of 65 years (range 42-85 years). These lesions included nine hyperplastic, three adenoma, and three hybrid types. Nuclear β-catenin localization was present in 7 of 13 lesions tested (54%). Next generation sequencing was successfully completed in 12 IDLs, of which seven (58%) had likely oncogenic mutations. These included three recurrent CTNNB1 mutations in hyperplastic (n = 2) and hybrid (n = 1) lesions and two recurrent HRAS hotspot mutations in adenomas.

conclusionDespite substantial heterogeneity, these findings confirm that a majority of IDLs are genuinely neoplastic, and some demonstrate molecular overlap with both BCA and EMC, supporting their theorized role as precursors to these tumors. Nevertheless, no oncogenic drivers were present in a significant subset of cases, suggesting that some IDLs may be truly reactive and hyperplastic. As such, IDL appear to represent a diverse morphologic and molecular spectrum that include both neoplastic and hyperplastic lesions. Reconsideration of the boundary between IDL and BCA in the future may be necessary to simplify classification.

Indexed as

AdenomaCarcinomaSalivary Gland NeoplasmsAdultAgedAged, 80 and overbeta CateninBiomarkers, TumorFemaleHumansMaleMiddle AgedMutationProto-Oncogene Proteins p21(ras)Salivary Ductsbeta CateninBiomarkers, TumorCTNNB1 protein, humanHRAS protein, humanProto-Oncogene Proteins p21(ras)Intercalated duct adenomaIntercalated duct hyperplasiaIntercalated duct lesionMolecular diagnosticsSalivary glands

Identifiers

PMID36480093
PMCPMC10293506
OpenAlexW4310962107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.